Nilotinib Accord

Nilotinib, the active ingredient in Nilotinib Accord, is a Tyrosine kinase inhibitor presented as a tablet for oral use. It treats chronic myeloid leukemia in the chronic phase and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients.

GNH USA supplies Nilotinib Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nilotinib is a targeted therapy that inhibits the BCR‑ABL tyrosine kinase pathway in certain blood cancers. - Chronic myeloid leukemia (CML) in chronic phase: reduces leukemic cell proliferation and improves survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): achieves remission by blocking BCR‑ABL signaling.

Nilotinib may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Rash: mild skin irritation or redness. - Nausea: feeling of sickness or urge to vomit. - Diarrhea: loose or frequent stools. - Elevated liver enzymes: increased ALT/AST levels detected in blood tests.

Serious or Rare Side Effects: - Cardiovascular events: including arterial occlusion, heart attack, or stroke. - Severe pancreatitis: inflammation of the pancreas with abdominal pain. - QT interval prolongation: heart rhythm disturbance that can lead to arrhythmia.

Before initiating therapy with Nilotinib, several safety considerations should be reviewed. - Cardiac assessment: evaluate history of cardiovascular disease and monitor ECG. - Liver function: check baseline hepatic enzymes and monitor periodically. - Electrolytes: correct low potassium or magnesium to reduce QT risk. - Drug interactions: avoid concomitant use of strong CYP3A4 inhibitors. - Pregnancy and lactation: contraindicated; ensure effective contraception for women of childbearing potential. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Nilotinib can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nilotinib plasma levels, risking toxicity. - Proton pump inhibitors (e.g., omeprazole) taken with nilotinib: can reduce absorption and efficacy. - Antacids containing aluminum or magnesium: may decrease nilotinib bioavailability.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower nilotinib concentrations, reducing therapeutic effect. - Concomitant QT‑prolonging drugs (e.g., amiodarone, fluoroquinolones): increase risk of cardiac arrhythmias; monitor ECG.